ASH 2021 Conference Coverage on VuMedi

 

ASH 2021 Conference Coverage on VuMedi
E

ASH 2021 Updates on Novel Advances in AML Therapy

By ASH 2021 Conference Coverage on VuMedi FEATURING Eunice Wang
By ASH 2021 Conference Coverage on VuMedi FEATURING Eunice Wang
218 views
December 20, 2021
0 Comments
Login to view comments. Click here to Login

Featured Video

13:04
Winship Cancer Institute - Emory University

Treatment-Related Quality of Life in MF

Feat. A. Hunter

Featured Video

15:14
Icahn School of Medicine at Mount Sinai

Safety Profile of Ruxolitinib in Patients With MF

Feat. D. Tremblay
Leukemia
06:56
ASH 2021 Conference Coverage on VuMedi

Acalabrutinib vs. Rituximab + Idelalisib/Bendamustine in R/R CLL: 3-…

Feat. P. Ghia
08:45
ASH 2021 Conference Coverage on VuMedi

ASH 2021 Updated Results From the Phase 3 QUAZAR AML-001 Trial: Long…

Feat. A. Wei
10:00
ASH 2021 Conference Coverage on VuMedi

ASH 2021 Updates on Asciminib vs. Investigator-Selected TKI in Newly…

Feat. J. Cortés
12:00
ASH 2021 Conference Coverage on VuMedi

ASH 2021 Highlights on ALLG Phase 2 INTERVENE Study: Investigating N…

Feat. C. Chua
08:50
ASH 2021 Conference Coverage on VuMedi

ASH 2021 Results From the SEQUOIA Study: Zanubrutinib vs. Bendamusti…

Feat. C. Tam
07:00
ASH 2021 Conference Coverage on VuMedi

ASH 2021 on a Study of Venetoclax and Low Dose Ara-C (VALDAC) to Tar…

Feat. T. Ing Soo
12:07
ASH 2021 Conference Coverage on VuMedi

ASH 2021 Long Term Follow-Up and Combined Phase 2 Results of Eprenet…

Feat. D. Sallman
11:06
ASH 2021 Conference Coverage on VuMedi

ASH 2021 MRD Assessment in CLL

Feat. P. Ghia
05:49
ASH 2021 Conference Coverage on VuMedi

ASH 2021 Update on the Safety & Efficacy of Menin Inhibition in …

Feat. E. Stein
08:38
ASH 2021 Conference Coverage on VuMedi

ASH 2021 Clinical Predictors of Outcomes in Adult Acute Leukemias an…

Feat. P. Desai
09:55
ASH 2021 Conference Coverage on VuMedi

ASH 2021: Comparing Outcomes Between CPX-351 and HMA+Ven As 1L Thera…

Feat. P. Desai
12:29
ASH 2021 Conference Coverage on VuMedi

ASH 2021 on Older Patients With AML: So I Am in Remission - Now What?

Feat. P. Desai
05:46
ASH 2021 Conference Coverage on VuMedi

ASH 2021: Outcomes of Patients Treated With CPX-351 as 1L Therapy fo…

Feat. A. Jain
21:44
ASH 2021 Conference Coverage on VuMedi

ASH 2021 Updates on Efficacy and AE Management of BTKi in CLL/SLL

Feat. J. Rhodes
11:34
ASH 2021 Conference Coverage on VuMedi

ASH 2021 Updates on Novel Advances in AML Therapy

Feat. E. Wang
17:05
ASH 2021 Conference Coverage on VuMedi

ASH 2021 Updates on Therapy of p53 Mutant Hematologic Malignancies

Feat. M. Davids
07:41
ASH 2021 Conference Coverage on VuMedi

ASH 2021 Update on BOVen in CLL: Early MRD Kinetics Define a High-Ri…

Feat. J. Soumerai
24:40
ASH 2021 Conference Coverage on VuMedi

ASH 2021 Update on MRD in ALL: Standard of Care & Areas for Furt…

Feat. L. Muffly
10:28
ASH 2021 Conference Coverage on VuMedi

ASH 2021 MRD Directed Therapy: A New Frontier in AML

Feat. A. Wei